Position in TLRY
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$80,085
-$59,554 QoQ
Shares Held
12,378
-20.0% QoQ
Ownership
0.011%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 78%
Shared 0%
None 22%
Common Shares in TLRY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Corient Private Wealth LLC holds $108,358,523 across 27 Drug Manufacturers - Specialty & Generic names. TLRY ranks #25 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
535,672 | $63,321,786 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
20,942 | $12,418,186 | |
| 3 | VTRS |
Viatris Inc
|
558,224 | $7,541,606 | |
| 4 | NBIX |
Neurocrine Biosciences Inc
|
45,035 | $5,932,910 | |
| 5 | ELAN |
Elanco Animal Health Inc
|
152,731 | $3,654,851 | |
| 6 | RDY |
Dr Reddys Laboratories Ltd
|
179,973 | $2,492,625 | |
| 7 | TEVA |
Teva Pharmaceutical Industries Ltd
|
51,664 | $1,556,119 | |
| 8 | TAK |
Takeda Pharmaceutical Co Ltd
|
80,361 | $1,488,285 |
All Filings in TLRY
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $80,085 | 12,378 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $139,639 | 15,464 | Shares | Sole | 2026-03-09 | |
| No filing history on record for this holder in this stock. | ||||||